Research Interest Statement:
My research is focus on developing natural killer (NK) cells for immunotherapeutic use against multiple myeloma, which has poor outcome despite novel therapeutic agents. In addition, elucidation of resistance mechanisms in myeloma is another area of my interest. Myeloma cells has the ability to evade immune surveillance through several potential mechanisms. Exploration of these mechanisms may lead to develop better therapeutic option in multiple myeloma.
Garg TK, Garg S, Miousse IR, [et al.]. Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model. International journal of molecular sciences. 2022 23(24). PMID: 36555814. PMCID: PMC9784560.
Garg S, Garg TK, Miousse IR, [et al.]. Effects of Gamma-Tocotrienol on Partial-Body Irradiation-Induced Intestinal Injury in a Nonhuman Primate Model. Antioxidants (Basel, Switzerland). 2022 11(10). PMID: 36290618. PMCID: PMC9598988.
Gai D, Chen JR, Stewart JP, [et al., including Garg TK]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476.
Garg S, Garg TK, Wise SY, [et al.]. Effects of Gamma-Tocotrienol on Intestinal Injury in a GI-Specific Acute Radiation Syndrome Model in Nonhuman Primate. International journal of molecular sciences. 2022 23(9). PMID: 35563033. PMCID: PMC9100017.